| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Koo Jakap serves as a Director at APUS. Across recent SEC filings that breaks down to 1 buy and 0 sells. Those positions are worth an estimated $3.0M at current prices.
The biggest single holding is APUS (~$3.0M) as Director. Net of sales, the recent Form 4 record there shows accumulation of 28,500 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 12, 2025 | APUS Apimeds Pharmaceuticals Us, Inc. | Director | Buy | 28,500 | $1.99 | $56,715.00 | +4.6% | -15.5% | -26.0% |